Skip Navigation


Rheumatology Advance Access originally published online on December 3, 2007
Rheumatology 2008 47(2):222; doi:10.1093/rheumatology/kem306
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/2/222-a    most recent
kem306v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bharadwaj, A.
Right arrow Articles by Hammond, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bharadwaj, A.
Right arrow Articles by Hammond, A.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTERS TO THE EDITOR

Use of parenteral methotrexate significantly reduces the need for biological therapy

A. Bharadwaj, S. Agrawal, M. Batley and A. Hammond

Department of Rheumatology, Maidstone Hospital, Maidstone ME16 9QQ, UK

Correspondence to: A. Bharadwaj. E-mail: Anurag.Bharadwaj@nhs.net

The first 10% of the full text of this article appears below.

SIR, According to current British Society for Rheumatology (BSR) guidelines, a patient with rheumatoid arthritis is entitled to receive anti-TNF therapy if the patient has failed on two DMARDs including methotrexate (MTX), and has a disease activity score (DAS) score more than 5.1 [1]. These guidelines have been introduced because of significant cost implications of biological treatment. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. Thornton, V. Ong, J. Ward, N. Kennedy, and A. Steuer
Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy
Rheumatology, September 1, 2008; 47(9): 1438 - 1438.
[Full Text] [PDF]